Monique E. Cho
( out of 96 reviews )

Monique E. Cho, MD

Languages spoken: English, Korean

Clinical Locations

Primary Location

Kidney & Liver Clinic

Kidney and Liver Clinic
50 N Medical Dr
Salt Lake City , UT 84132
801-581-2772
Get Directions

University of Utah Hospital

Nephrology
50 N Medical Dr
Salt Lake City , UT 84132
Get Directions

Moniqué E. Cho, M.D. is an Associate Professor in the Department of Medicine, Division of Nephrology & Hypertension. Dr. Cho received her B.A. degree in Psychology from Cornell University, NY and M.D. degree from Dartmouth Medical School, NH. She completed her Internal Medicine residency and Nephrology fellowship at the University of Rochester in New York. Dr. Cho's research interest focuses on the efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibition to improve vascular and physical function in patients with chronic kidney disease.

Specialties

Patient Rating

Patients consistently praise Dr. Cho for her expertise, thoroughness, and ability to explain complex issues in clear, understandable terms. Many comment that she is compassionate, attentive, and takes time to listen, answer questions, and develop a clear, research-informed plan of care. Her organized, caring team and thoughtful bedside manner leave patients feeling reassured and confident in their treatment.

Generated via Patient Reviews

5.0 /5
( out of 96 reviews )

The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers. The scale on which responses are measured is 1 to 5 with 5 being the best score.

Moniqué E. Cho, M.D. is an Associate Professor in the Department of Medicine, Division of Nephrology & Hypertension. Dr. Cho received her B.A. degree in Psychology from Cornell University, NY and M.D. degree from Dartmouth Medical School, NH. She completed her Internal Medicine residency and Nephrology fellowship at the University of Rochester in New York. Dr. Cho's research interest focuses on the efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibition to improve vascular and physical function in patients with chronic kidney disease.

Board Certification and Academic Information

Academic Departments Internal Medicine -Associate Professor
Academic Divisions Nephrology & Hypertension

Education history

Professional Other Training Program in Clinical Research - Duke University/NIH (Training Program in Clinical Research) Senior Clinical Fellow
Fellowship Kidney Disease Branch - National Institute of Diabetes and Digestive and Kidney Diseases Senior Clinical Fellow
Fellowship Nephrology - University of Rochester Medical Center Fellow
Residency Internal Medicine - University of Rochester Medical Center Resident
Internship General Internal Medicine - Rhode Island Hospital Intern
Professional Medical Medicine - Geisel School of Medicine at Dartmouth M.D.
Graduate Training Harvard Extension School Postbaccalaureate Studies
Undergraduate Psychology - Cornell University B.A.

Selected Publications

Journal Article

  1. Brinker L, Sideris K, Wei G, Singh R, Nevers MR, Hartsell SE, Sarwal A, Kyriakopoulos CP, Tseliou E, Benes J, Melenovsky V, Drakos SG, Hanff TC, Carter S, Fang JC, Cho M, Beddhu S, Stehlik J (2025). Diabetes Therapy With SGLT2i After Heart Transplant: A Multi-Institutional Analysis. JACC Heart Fail, 13(8), 102520.
  2. Shiu YT, Northrup H, Huang Y, Cho ME, Bunsawat K (2025). Cellular and molecular mechanisms underlying hemodialysis arteriovenous fistula dysfunction and approaches to promote maturation: A vascular perspective. . Am J Physiol Heart Circ Physiol.
  3. Cho ME, Brunt VE, Shiu YT, Bunsawat K (2025). Endothelial dysfunction in chronic kidney disease: a clinical perspective. . Am J Physiol Heart Circ Physiol.
  4. Koyama AK, Nee R, Yu W, Choudhury D, Heng F, Cheung AK, Cho ME, Norris KC, Yan G (2024). Homelessness and Risk of End-Stage Kidney Disease and Death in Veterans With Chronic Kidney Disease. JAMA Netw Open, 7(9), e2431973.
  5. Dolui S, Detre JA, Gaussoin SA, Herrick JS, Wang DJJ, Tamura MK, Cho ME, Haley WE, Launer LJ, Punzi HA, Rastogi A, Still CH, Weiner DE, Wright JT Jr, Williamson JD, Wright CB, Bryan RN, Bress AP, Pajewski NM, Nasrallah IM (2022). Association of Intensive vs Standard Blood Pressure Control With Cerebral Blood Flow: Secondary Analysis of the SPRINT MIND Randomized Clinical Trial. JAMA Neurol, 79(4), 380-389.
  6. Mehta RC, Cho ME, Cai X, Lee J, Chen J, He J, Flack J, Shafi T, Saraf SL, David V, Feldman HI, Isakova T, Wolf M, CRIC Study Investigators (2021). Iron status, fibroblast growth factor 23 and cardiovascular and kidney outcomes in chronic kidney disease. Kidney Int, 100(6), 1292-1302.
  7. Cho ME, Hansen JL, Peters CB, Cheung AK, Greene T, Sauer BC (2019). An increased mortality risk is associated with abnormal iron status in diabetic and non-diabetic Veterans with predialysis chronic kidney disease. Kidney Int, 96(3), 750-760.
  8. Agarwal A, Cheung AK, Ma J, Cho M, Li M (2019). Effect of Baseline Kidney Function on the Risk of Recurrent Stroke and on Effects of Intensive Blood Pressure Control in Patients With Previous Lacunar Stroke: A Post Hoc Analysis of the SPS3 Trial (Secondary Prevention of Small Subcortical Strokes). J Am Heart Assoc, 8(16), e013098.
  9. Upadhya B, Lovato LC, Rocco M, Lewis CE, Oparil S, Cushman WC, Kostis JB, Rodriguez CJ, Cho ME, Cloud LW, Rastogi A, Rosendorff C, Kitzman DW (2019). Heart failure prevention in older patients using intensive blood pressure reduction: Potential role of diuretics. JACC Heart Fail, 7(12), 1032-1041.
  10. Upadhya B, Rocco MV, Pajewski NM, Morgan T, Blackshear J, Hundley WG, Oparil S, Soliman EZ, Cohen DL, Hamilton CA, Cho ME, Kostis WJ, Papademetriou V, Rodriguez CJ, Raj DS, Townsend R, Vasu S, Zamanian S, Kitzman DW, SPRINT Research Group (2019). Effect of Intensive Blood Pressure Reduction on Left Ventricular Mass, Structure, Function, and Fibrosis in the SPRINT-HEART. Hypertension, HYPERTENSIONAHA11913073.
  11. Cho ME, Craven TE, Cheung AK, Glasser SP, Rahman M, Soliman EZ, Stafford RS, Johnson KC, Bates JT, Burgner A, Taylor AA, Tamariz L, Tang R, Beddhu S, SPRINT Study ResearchGroup (2017). The association between insulin resistance and atrial fibrillation: A cross-sectional analysis from SPRINT (Systolic Blood Pressure Intervention Trial). J Clin Hypertens (Greenwich), 19(11), 1152-1161.
  12. Soliman EZ, Ambrosius WT, Cushman WC, Zhang ZM, Bates JT, Neyra JA, Carson TY, Tamariz L, Ghazi L, Cho ME, Shapiro BP, He J, Fine LJ, Lewis CE, SPRINT Research Study Group (2017). Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Hypertension: SPRINT (Systolic Blood Pressure Intervention Trial). Circulation, 136(5), 440-450.
  13. Chen X, Wei G, Jalili T, Metos J, Giri A, Cho ME, Boucher R, Greene T, Beddhu S (2016). The Associations of Plant Protein Intake With All-Cause Mortality in CKD. Am J Kidney Dis, 67(3), 423-30.
  14. Bhattacharyya N, Wiench M, Dumitrescu C, Connolly BM, Bugge TH, Patel HV, Gafni RI, Cherman N, Cho M, Hager GL, Collins MT (2012). Mechanism of FGF23 processing in fibrous dysplasia. J Bone Miner Res, 27(5), 1132-41.
  15. Chen X, Summers RM, Cho M, Bagci U, Yao J (2012). An automatic method for renal cortex segmentation on CT images: evaluation on kidney donors. Acad Radiol, 19(5), 562-70.
  16. Sharma K, Ix JH, Mathew AV, Cho M, Pflueger A, Dunn SR, Francos B, Sharma S, Falkner B, McGowan TA, Donohue M, Ramachandrarao S, Xu R, Fervenza FC, Kopp JB (2011). Pirfenidone for diabetic nephropathy. J Am Soc Nephrol, 22(6), 1144-51.
  17. Cho ME, Duan Z, Chamberlain CE, Reynolds JC, Ring MS, Mannon RB (2010). Cinacalcet improves bone density in post-kidney transplant hyperparathyroidism. Transplant Proc, 42(9), 3554-8.
  18. Kopp JB, Smith MW, Nelson GW, Johnson RC, Freedman BI, Bowden DW, Oleksyk T, McKenzie LM, Kajiyama H, Ahuja TS, Berns JS, Briggs W, Cho ME, Dart RA, Kimmel PL, Korbet SM, Michel DM, Mokrzycki MH, Schelling JR, Simon E, Trachtman H, Vlahov D, Winkler CA (2008). MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet, 40(10), 1175-84.
  19. Zhou H, Cheruvanky A, Hu X, Matsumoto T, Hiramatsu N, Cho ME, Berger A, Leelahavanichkul A, Doi K, Chawla LS, Illei GG, Kopp JB, Balow JE, Austin HA 3rd, Yuen PS, Star RA (2008). Urinary exosomal transcription factors, a new class of biomarkers for renal disease. Kidney Int, 74(5), 613-21.
  20. McKenzie LM, Hendrickson SL, Briggs WA, Dart RA, Korbet SM, Mokrzycki MH, Kimmel PL, Ahuja TS, Berns JS, Simon EE, Smith MC, Trachtman H, Michel DM, Schelling JR, Cho M, Zhou YC, Binns-Roemer E, Kirk GD, Kopp JB, Winkler CA (2007). NPHS2 variation in sporadic focal segmental glomerulosclerosis. J Am Soc Nephrol, 18(11), 2987-95.
  21. Cho ME, Smith DC, Branton MH, Penzak SR, Kopp JB (2007). Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clin J Am Soc Nephrol, 2(5), 906-13.
  22. Cho ME, Hurley JK, Kopp JB (2007). Sirolimus therapy of focal segmental glomerulosclerosis is associated with nephrotoxicity. Am J Kidney Dis, 49(2), 310-7.

Review

  1. Cho ME, Beddhu S (2016). Dietary recommendations for patients with nondialysis CKD. [Review]. UpToDate.
  2. Beddhu S, Cho ME, Bansal S (2016). Pathogenesis and treatment of malnutrition in maintenance hemodialysis patients. [Review]. UpToDate.
  3. Bansal S, Cho ME, Beddhu S (2016). Assessment of nutritional status in hemodialysis patients. [Review]. UpToDate.